Abu Dhabi’s TII and NVIDIA Launch Middle East’s First Joint ‘AI & Robotics’ NVAITC Research Lab
22.9.2025 12:34:00 EEST | Business Wire | Press release
The Technology Innovation Institute (TII), the applied research arm of Abu Dhabi’s Advanced Technology Research Council (ATRC), has joined forces with NVIDIA, the world leader in accelerated computing and AI, to launch the Middle East’s first Joint Lab dedicated to both artificial intelligence and robotics. This landmark collaboration establishes a first-of-its-kind hub in the region for developing next-generation AI models, robotics platforms, and humanoid technologies that will accelerate innovation across industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250922672333/en/
Abu Dhabi’s TII and NVIDIA Launch Middle East’s First Joint ‘AI & Robotics’ NVAITC Research Lab (Photo: AETOSWire)
The announcement of the TII-NVAITC (NVIDIA AI Technology Center) Joint Lab for AI and Robotics was made during a signing ceremony held at TII’s headquarters in Abu Dhabi, bringing together senior leaders from both organizations. The agreement was signed by Dr Najwa Aaraj, CEO of TII and Marc Domenech, Regional Director, Enterprise – META Region at NVIDIA, in the presence of H.E. Shahab Abu Shahab, Director General at ATRC, H.E. Abdulaziz Al Dosari, Executive Director of Support Services at ATRC, John Josephakis, Global VP of Sales and Business Development for HPC/Supercomputing at NVIDIA, and Simon See, Global Head NVIDIA AI Technology Centre at NVIDIA, marking a milestone moment in the UAE’s AI and robotics journey.
The collaboration places Abu Dhabi at the forefront of applied AI, aligning with the emirate’s long-term strategy to advance technological sovereignty and shape the future of intelligent autonomous systems. It also underscores the UAE’s growing role as a global AI and Robotics leader – highlighted by the recent US–UAE AI Acceleration Partnership – and positions the country as a major contributor to the global robotics ecosystem at a time when AI capabilities are rapidly evolving.
“This collaboration with NVIDIA marks a major step toward building AI-enhanced robotic systems capable of reasoning, adapting, and acting in complex environments,” said Dr. Najwa Aaraj, CEO of TII. “By combining our advanced robotic platforms with powerful AI models and compute, we are accelerating the convergence of perception, control, and language – laying the foundation for a new era of intelligent machines.”
The TII-NVAITC Joint Lab will integrate NVIDIA accelerated computing platforms and expertise with TII’s multidisciplinary research in AI, robotics, autonomous systems, and high-performance computing. It is the first NVAITC lab established in the Middle East, marking a significant milestone for the region. Together, the two organizations will accelerate the development of intelligent systems with real-world applications – advancing the field of Physical AI through embodied AI models, state-of-the-art robotics and humanoid stacks, and hardware designed for real-time robotic systems. Research will span robotic learning and control at scale, as well as the development and integration of large language models, including TII’s Falcon family of AI models – among them the Middle East’s first and largest AI models.
“The launch of the TII-NVAITC for AI and Robotics marks a new chapter in our global NVAITC network. By working with TII in Abu Dhabi, we are expanding the scope of these centers into robotics for the first time in the Middle East - helping researchers and innovators accelerate breakthroughs that will shape the future of intelligent systems,” said Carlo Ruiz, Vice President - Enterprise Solutions & Operations EMEA at NVIDIA.
This new lab forms part of TII’s broader strategy to advance applied AI and robotics that deliver real-world impact. At its core is a commitment to open innovation and global knowledge exchange, with TII and NVIDIA collaborating on research, open-source initiatives, and cross-network learning through the global NVAITC community. The lab also builds on TII’s existing modular robotic platforms and field-tested components, including robotic arms and delivery dogs, prioritizing research that is grounded in both technical excellence and practical readiness.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250922672333/en/
Contacts
Jinan Warrayat,
+971504713552, jinan.warrayat@tii.ae
tii@edelman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom